

Pharmacy BULLETIN BOARD

Industry Issue ■ Monday June 23, 2014

UriSec® emollient creams and lotions are patient friendly formulations ideal for winter dryness and itchy skin.

Product	Sizes	Odan Code	Kohl & Frisch Code	McKesson Code	McMahon Code
UriSec® 10% Cream NPN 80005397	75 g	38075	32617	513085	26638401
	120 g	38045	32618	513341	26638301
UriSec 12% Lotion NPN 00514896	250 mL	230J	48909	115493	26623101
	120 g	220Q	46312	115444	26623201
UriSec® 22% Cream NPN 00396125	225 g	220C	-	153486	26537801
	454 g	220R	46309	848549	26632301
UriSec® 40 Cream NPN 80005531	15 g	45014	114939	003743	-
	30 g	45028	32606	799437	27127401
	100 g	45067	32616	799494	26640001

UriSec® products are prescribed by Dermatologists and Physicians and are used by both patients and hospitals across Canada.

To order, please contact your wholesaler or Odan at 1-800-387-9342 or by e-mail at info@odanlab.com. You can also visit our website at www.odanlab.com



UriSec® is a registered trademark of Odan Laboratories Ltd.

BURLINGTON, ON: Results from a Phase III 52 week study, show tiotropium (delivered via Respimat®) 5µg, a once-daily long-acting anticholinergic bronchodilator, is efficacious and well-tolerated as an add-on treatment in Japanese adults with moderate to severe symptomatic asthma, despite treatment with inhaled corticosteroids (ICS) with or without long-acting beta-2 agonist (LABA).

FROM THE NEWSWIRE

MISSISSAUGA: Women with HER2-positive metastatic breast cancer in Manitoba will now be able to access a new treatment option through CancerCare Manitoba. The Provincial Oncology Drug Program has approved the addition of KADCYLA® (trastuzumab emtansine) to the CancerCare Manitoba Drug Formulary. CancerCare Manitoba has approved KADCYLA as second line treatment for patients with HER2-positive, unresectable locally advanced or metastatic breast cancer with an ECOG performance status equal to or less than two, who have received prior treatment with trastuzumab plus chemotherapy in the metastatic setting or have disease recurrence during or within six months of completing adjuvant therapy with trastuzumab plus chemotherapy.

MARKHAM, ON: Astellas Pharma Canada, Inc. ("Astellas"), a Canadian subsidiary of Tokyo-based Astellas Pharma Inc., has announced that Health Canada has now approved once-daily Advagraf® (tacrolimus extended release capsules) for prophylaxis of organ rejection in adult patients receiving liver transplants. Tacrolimus extended release capsules are also approved in Canada for prophylaxis of organ rejection in adult patients receiving allogeneic kidney transplants.

OTTAWA: Health Canada published the first results from the Maternal-Infant Research on Environmental Chemicals (MIREC) Study that examined phthalate and Bisphenol A (BPA) exposure among pregnant Canadian women. The results of the study are significant. They provide much-needed information on the levels of phthalates and BPA present in one of our most susceptible subpopulations, pregnant women, as well as a basis for continued monitoring.

BURLINGTON and TORONTO, ON: Eli Lilly and Company and Boehringer Ingelheim Pharmaceuticals Inc. presented data showing that LY2963016*, the alliance's investigational new insulin glargine product, has a similar safety and efficacy profile to currently marketed insulin glargine (Lantus®). Results from these Phase I and Phase III studies were presented at the 74th American Diabetes Association Scientific Sessions in San Francisco.

To include your communication in the next issue, please contact: Health Response

T: 416-863-5403 | F: 416-863-9620 | hrc@healthresponse.ca

Next Issue: Monday July 7th, 2014

Deadline: Thursday July 3rd, 2014